On March 11, 2022 InnoCure Therapeutics (hereinafter referred to as InnoCure), a new drug development bio-venture, reported the company has completed Series A funding (Press release, InnoCure Therapeutics, MAR 11, 2022, View Source;mode=view&idx=6&sk=&sw=&offset=20&category= [SID1234651741]). Four investment institutions participated and successfully raised a total of 5.5 billion won. Based on this funding, it plans to secure leading substances for preclinical chronic myeloid leukemia treatment, Parkinson’s disease, and RAS-specific mutant protein targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the financial investment industry on the 19th, InnoCure raised 5.5 billion won in funds by issuing redeemable convertible preferred stocks. The four institutions that participated in InnoCure’s Series A funding are Starset Investment, Laguna Investment, Suin Investment, and G&Tech Venture Investment.

InnoCure is seeking to be listed on KOSDAQ in 2024 and aims to IPO through a technology special case method when the global clinical entry of three or more products becomes visible.

InnoCure is a bio venture that develops new drugs using the next-generation protein degradation mechanism PROTAC (Proteolysis-Targeting Chimaera) technology. It was founded in January 2018 by CEO Yoo Hye-dong, who participated in the development of new drugs such as the development of alternative drugs for the nano-anticancer drug Abraxane at Celgene.

Based on Series A funding, InnoCure plans to complete preclinical trials for the T315I mutation treatment for chronic myeloid leukemia using PROTAC technology by mid-2022. It is also focusing on securing a leading substance that selectively decomposes RAS-specific mutant proteins that were difficult to approach with small-molecule inhibitor development methods.

PROTAC is an innovative technology that can fundamentally decompose undruggable target proteins that were difficult to approach with existing small-molecule compound methods. PROTAC’s catalytic function is used to achieve high therapeutic effects with small doses, reduce side effects, and overcome resistance to existing treatments, so it is being used in the development of cancer or intractable disease treatments.

On March 11, 2022 Cannabics Pharmaceuticals Inc. (the "Company") reported that it entered into a forbearance agreement (the "Agreement") with an institutional investor (the "Investor") relating to that certain Senior Secured Promissory Note in the original principal amount of $1,375,000 due on December 21, 2021 (the "February Note") (Filing, 8-K, Cannabics Pharmaceuticals, MAR 11, 2022, View Source [SID1234610151]). The February Note was issued by the Company to the Investor in connection with that certain Securities Purchase Agreement dated as of December 16, 2020, and amended as of February 22, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Agreement, the Investor, through May 7, 2022 (the "Forbearance Period"), agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments under the February Note and to waive certain other defaults under the February Note and related rights pursuant to the Registration Rights Agreement entered into in December 2020 between the Company and the Investor (the "Registration Rights Agreement"). This description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Forbearance Agreement filed as Exhibit 10.1 to this report and is incorporated herein by reference.

As previously described in a Form 8-K filed with the Securities and Exchange Commission on February 17, 2022, on February 15, 2022 the Company entered into a forbearance agreement with the Investor relating to the February Note pursuant to which the Investor had agreed to forbear, through March 7, 2022, from exercising any rights and remedies against the Company related to the outstanding payments under the February Note and to waive certain other defaults under the February Note and related rights pursuant to the Registration Rights Agreement.

On March 11, 2022 Helix BioPharma Corp. (TSX: "HBP") ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today anreportednounces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share (Press release, Helix BioPharma, MAR 11, 2022, View Source [SID1234610028]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the Company announces that it has applied to the Toronto Stock Exchange (the "TSX") to introduce an
Incentive Plan (as defined below) to temporarily reduce the exercise price of its issued and outstanding common
share purchase warrants ("Warrants") that are not held by insiders of the Company, or non-arm’s length parties,
including all such Warrants expiring on March 31, 2022 to May 12, 2026 ("Eligible Warrants"), from their current
respective exercise prices to a reduced exercise price of $0.26 (the "Incentive Exercise Price").

Private Placement
Mr. Jerzy Wilczewski ("Mr. Wilczewski"), an insider of the Company, subscribed for all 3,850,000 of the common
shares issued under the private placement. As a result of the closing of the private placement, Mr. Wilczewski owns,
or exercises control or direction over, 23,467,153 common shares, representing approximately 15.94% of the issued
and outstanding common shares of the Company on a non-diluted basis, or approximately 24.95% on a partially
diluted basis, assuming the full exercise of the 17,659,500 common share purchase warrants that Mr. Wilczewski
owns or exercises control or direction over.

"I strongly believe in the new strategy and look forward to further advancements of the company’s L-DOS47 drug
platform" said Mr. Wilczewski. "We are very appreciative of Mr. Wilczewski’s continued support" said Dr. Majewski,
Helix’s Interim Chief Executive Officer.
The Company intends to use the net proceeds of the private placement for working capital and advancing the
Company’s L-DOS47 drug development program.

The purchase of common shares by Mr. Wilczewski is considered a "related party transaction" within the meaning of
Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61- 101"). The
Company relied on exemptions from the formal valuation and minority approval requirements in sections 5.5(a) and
5.7(1)(a) of MI 61-101 in respect of Mr. Wilczewski ‘s purchase of common shares. The Company did not file a material change report in respect of the related party transaction less than 21 days prior to the closing of the private
placement, which the Company deems reasonable in the circumstances so as to be able to avail itself of the proceeds of the private placement in an expeditious manner.

Warrant Incentive Program
The Company has applied to the TSX to temporarily reduce the exercise price of all of its issued and outstanding
Eligible Warrants, being those Warrants that are not held by insiders of the Company or non-arm’s length parties,
including all such Warrants expiring on March 31, 2022 to May 12, 2026, from their current respective exercise prices
ranging from $0.70 to $1.98 to a reduced Incentive Exercise Price of $0.26 as an incentive (the "Incentive Program") to the holders of Eligible Warrants to exercise such Eligible Warrants over a limited period commencing on March 28, 2022 until April 28, 2022 (the "Early Exercise Period"). The implementation of the Incentive Program is subject to the approval of the TSX.

Proceeds received by the Company from the exercise of Eligible Warrants, if any, will be used for working capital and
advancing the Company’s L-DOS47 drug development program. The terms and conditions of the Incentive Program
and the method of exercising Eligible Warrants pursuant to the Program will be set forth in a letter which will be
delivered to each holder of Eligible Warrants at their registered address. New certificates representing the Eligible
Warrants will not be issued in connection with the Incentive Program.

The Eligible Warrants include an aggregate of 49,806,469 warrants that if exercised at the Incentive Exercise Price
will result in the Company receiving gross proceeds of up to $12,949,682 There can be no assurances as to the
number of Eligible Warrants that will be exercised under the Incentive Program or if any Eligible Warrants will be
exercised under the Incentive Program at all.

The dates of each private placement under which the Eligible Warrants were issued, the original issue price of the
units of which the Eligible Warrants formed a part of, the total number of Eligible Warrants, the original exercise price
of the Eligible Warrants, the current expiry dates of the Warrants and the proposed Incentive Exercise Price of the
Eligible Warrants are as follows:

In connection with the proposed adoption of the Incentive Program, the Company also announces that it is extending the exercise period of a total of 3,680,000 Warrants (the "Extended Warrants"), all of which are held by arm’s length parties, until April 28, 2022 (the "Warrant Extension"). The Extended Warrants were issued pursuant to a private placement of the Company that closed in April 2015, have a current exercise price of $1.54 (prior to the contemplated adjustment pursuant to the Incentive Program) and an expiry date of March 31, 2022 and represent approximately 2.55 % of the Company’s issued and outstanding Common Shares. The expiry date of the Extended Warrants is being extended in order to provide the holders of such Warrants with the opportunity to exercise their Extended Warrants pursuant to the terms of the Incentive Program. The Warrant Extension is subject to the approval of the TSX.

On March 11, 2022 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, reported its leadership’s participation in two upcoming Investor Conferences this month (Press release, Renovorx, MAR 11, 2022, View Source [SID1234610011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ROTH Capital Partners 34th Annual Conference
Format and Dates: In person, March 13-15, 2022
Location: The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA
Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on Monday, March 14th at 1:30 p.m. PT
Webcast: View Source
Register: Visit the event website

Maxim Virtual Growth Conference
Format and Dates: Virtual, March 28-30, 2022
Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on-demand
Webcast: https://m-vest.com/events/2022-virtual-growth-conference
Register: Visit the event website

Maxim Growth Conference Panel on Pancreatic Cancer
Format and Date: Virtual, Monday March 28, 12:00 – 1:00 pm ET
Presenter: Shaun Bagai, CEO, to participate with other industry leaders on pancreatic cancer panel.
Webcast: A link to this panel will be posted to the RenovoRx Website Events page when it becomes available.

RenovoRx leadership will be available during the events for one-on-one meetings with the investment community. To schedule a meeting please reach out to your respective conference representative or by emailing KCSA Strategic Communications: [email protected].

On March 11, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported a business update and an update on its cash position at the end of December 2021 (Press release, ERYtech Pharma, MAR 11, 2022, View Source [SID1234610008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Notwithstanding the setback of our Phase 3 trial in pancreatic cancer not meeting its primary endpoint, 2021 has been a year of important achievement for Erytech," said Gil Beyen, CEO of ERYTECH. "We are very encouraged by the progress we are making towards seeking an approval for our lead product candidate GRASPA for the treatment of ALL patients who experienced hypersensitivities to pegylated asparaginase. Our BLA is ready to be submitted quickly once the FDA will have completed its review of the last information requests and gives us the green light to submit. The review of our strategic options is advancing well and different partnering discussions are in advanced stages of negotiation."

Business Highlights

Path to BLA in hypersensitive ALL, based on results of NOPHO-sponsored Phase 2 trial

The NOPHO trial evaluated the safety and pharmacological profile of eryaspase in acute lymphoblastic leukemia (ALL) patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy. In December 2020, positive trial results were presented at the 2020 American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting.

Eryaspase, also referred to as GRASPA, its recently approved invented name, in combination with chemotherapy and administered every two weeks, provided a sustained asparaginase enzyme activity level, and was generally well tolerated with few hypersensitivity reactions.

The Company pursues its interactions with the U.S. Food and Drug Administration (FDA) regarding a potential regulatory approval in this indication based on the NOPHO-sponsored trial. A pre-BLA meeting to discuss the submission of a Biologics License Application (BLA) took place in June 2021 after which the Company confirmed its intention to submit a BLA subject to successful completion of remaining activities.
In July 2021, the Company announced that the FDA had granted eryaspase Fast Track designation for the treatment of ALL patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.
The BLA application is now almost completed, allowing a fast submission once the FDA has finalized its review of the remaining information requests and gives the green light to file.

TRYbeCA-1, pivotal Phase 3 clinical trial in second-line advanced pancreatic cancer

As reported in October 2021, the Phase 3 TRYbeCA-1 trial did not meet the primary efficacy endpoint of overall survival (OS). The median OS for patients treated with eryaspase plus chemotherapy was 7.5 months, compared to 6.7 months for chemotherapy alone, with an OS hazard ratio (HR) of 0.92 in the intent-to-treat (ITT) population (p-value 0.375).

The prespecified subgroup of patients treated with eryaspase and FOLFIRI, an irinotecan-based chemotherapy, demonstrated a nominal increase in median OS of 2.3 months, from 5.7 to 8 months (HR = 0.77; per protocol population), which the Company believes merits further investigation.
Patients treated with eryaspase demonstrated improved disease control compared to patients treated with chemotherapy only. Other secondary endpoints showed nominal improvement.
The safety profile of eryaspase was consistent with earlier clinical trials results and safety reviews.
Final data of the trial were presented as a late-breaking oral presentation at ASCO (Free ASCO Whitepaper)-GI in January 2022.
Potential continuation of development in pancreatic cancer was discussed with Key Opinion Leaders, who confirmed that further exploration of the combination of eryaspase with irinotecan- and fluoropyrimidine-based chemotherapy is of interest, and who recommended to consider further development in later lines of treatment.

rESPECT, Phase 1 investigator-sponsored trial (IST) in first-line pancreatic cancer

rESPECT is a Phase 1 trial, sponsored by the Georgetown Lombardi Comprehensive Cancer Center, evaluating the safety of eryaspase in combination with mFOLFIRINOX as a first-line treatment for locally advanced and metastatic pancreatic cancer in approximately 18 patients.

Patient enrollment started in January 2021, and the first dose cohort (75 U/kg) of three patients was enrolled by the end of February. No dose-limiting toxicity (DLT) was observed, and the trial was escalated to the next dosing cohort (100 U/kg).
After review of the safety data in the first two dose cohorts, the dose escalation committee concluded that the novel combination of mFOLFIRINOX plus eryaspase was well tolerated with no dose limiting toxicity. Consequently, the maximum tolerated dose (MTD) was determined at a dose of 100 U/kg eryaspase.
Interim data, presented as ASCO (Free ASCO Whitepaper) GI in January 2022, confirmed the acceptable safety profile and showed encouraging clinical activity. Out of the twelve patients enrolled, ten patients have been evaluated for response. They all achieved disease control; five patients with objective response and five with stable disease.

The trial will continue enrolling up to approximately 18 patients. Reporting of final data is expected in the third quarter of 2022.

TRYbeCA-2, randomized Phase 2 clinical trial in triple-negative breast cancer (TNBC)

The TRYbeCA-2 trial is evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone, in metastatic TNBC. Target enrollment is approximately 64 patients. The primary end point of the trial is objective response rate.

Following the disappointing results of eryaspase in combination with a gemcitabine-based chemotherapy in the TRYbeCA-1 trial in second-line pancreatic cancer, the Company has, in consultation with the trial’s Steering Committee, decided to stop further enrollment in the TRYbeCA-2 trial.

The results of the patients enrolled in the TRYbeCA-2 trial to date are expected to be reported around mid 2022.

Process to review strategic options and partnering alternatives well advanced

As announced on October 25th 2021, the Company has appointed a specialized advisor to evaluate its strategic and partnering options. The process is ongoing and different partnering opportunities are in advanced stage of negotiations.

Update on Q4 2021 Financial Results and Cash Position

As of December 31, 2021, ERYTECH had cash and cash equivalents totaling €33.7 million (approximately $38.1 million), compared with €44.4 million as of December 31, 2020 and €38.0 million on September 30, 2021. The €10.7 million decrease in cash position during the twelve months of 2021 was the result of a €57.1 million net cash utilization in operating activities and investing activities and €44.7 million generated in financing activities, including €34.6 million in combined net proceeds from the at-the-market (ATM) equity financing program, two Registered Direct offerings in April ($30M) and December ($7.85M), and €11.4 million from the drawdown of four tranches of convertible notes (OCABSA), while the variation of the U.S. dollar against the euro led to a €1.3 million positive currency exchange impact.
The Company believes that its current cash position, without considering future proceeds from potential strategic options, can fund its planned operating expenses and current programs well into the third quarter of 2022.
Given its ongoing discussions, the Company will need to present proforma FY2021 accounts per market regulation, to reflect the potential impact of a transaction on its operations. Consequently and given the time needed to prepare, audit and review proforma accounts with market regulators, the Company is postponing the reporting of its FY2021 financial results to a later date in April.

Key News Flow and Milestones Expected Over the Next 12 Months

Planned BLA submission of eryaspase in hypersensitive ALL (Q2 2022)
Data from the randomized Phase 2 TRYbeCA-2 trial of eryaspase in TNBC (Q3 2022)
Results from the Phase 1 rESPECT Trial of eryaspase in combination with mFOLFIRINOX in first-line pancreatic cancer (2H 2022)

Fourth Quarter and Full Year 2021 Conference Call Details

ERYTECH management will hold a conference call and webcast on Monday, March 14, 2021 at 8:30am EDT / 1:30 pm CET to discuss the recent business and financial updates. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session.

The audio call is accessible via the below registering link: View Source (Conference ID : 1086874)

Once registered, participants will receive a unique access code and the call number details to join the teleconference.

The webcast can be followed live online via the link: View Source

An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 1086874#.

An archive of the webcast will be available on ERYTECH’s website, under the "Investors" section at investors.erytech.com

ERYTECH plans on attending the following upcoming investor conferences:

Investor Access Conference, April 4-5, Paris
Kempen Life Science Conference 2022, April 20-21, Amsterdam
Jefferies 2022 Global Healthcare Conference, June 8-10, New York